A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.

Benjamin SolomonAna CallejoJair BarGuy BerchemLyudmila BazhenovaPierre SaintignyFanny WunderJacques RaynaudNicolas GirardJ Jack LeeRaed SulaimanBruce ProuseCatherine BressonHila VenturaShai MagidiEitan RubinBrandon YoungAmir OnnBrian Leyland-JonesRichard L SchilskyVladimir LazarEnriqueta FelipRazelle Kurzrock

Published in: Cancer medicine (2022)

Overall, eight of 15 patients (53%) achieved clinical benefit (SD ≥ 24 weeks/PR) on the avelumab, axitinib, and palbociclib combination. This triplet showed antitumor activity in NSCLC, including in tumors post-pembrolizumab progression, and was active at the RP2D, which was well tolerated. NCT03386929 clinicaltrial.gov.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
end stage renal disease
chronic kidney disease
ejection fraction
small cell lung cancer
newly diagnosed
prognostic factors
metastatic renal cell carcinoma
patient reported outcomes
preterm birth